title: A case of panitumumab-responsive metastatic rectal cancer initially refractory to cetuximab.
abstract: A 64-year-old man was initially diagnosed with rectal cancer and liver metastasis. He underwent rectal amputation and partial hepatectomy. mFOLFOX6 was begun as first-line chemotherapy, but multiple pulmonary and right femoral lymph node metastases were found 1 year postoperatively. FOLFIRI plus bevacizumab was then started, but the tumors recurred after 2 years and 11 months. The regimen was changed to cetuximab with CPT-11. The lesions partially responded after 3 months, and the patient was free from progression for 1.5 years. Four years and 7 months after the adjuvant chemotherapy was started, the metastatic lesions gradually increased again, and the regimen was changed to panitumumab. After 2 months, the lesions had markedly decreased again and showed a partial response for 6 months. Although the pulmonary lesions became progressive again, the patient has been alive for 5 years and 8 months since the first operation.
authors.affiliation: Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
authors.forename: Yuta
authors.initials: Y
authors.lastname: Kasagi
authors.forename: Eiji
authors.initials: E
authors.lastname: Oki
authors.forename: Koji
authors.initials: K
authors.lastname: Ando
authors.forename: Yasue
authors.initials: Y
authors.lastname: Kimura
authors.forename: Toru
authors.initials: T
authors.lastname: Ikegami
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Saeki
authors.forename: Masaru
authors.initials: M
authors.lastname: Morita
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Kusumoto
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Maehara
keywords: Cetuximab-resistant rectal cancer; Epidermal growth factor receptor mutation; Panitumumab
references.citation: Sci Transl Med. 2011 Sep 7;3(99):99ra86
references.pmid: 21900593
references.citation: J Clin Oncol. 2010 Nov 1;28(31):4706-13
references.pmid: 20921462
references.citation: Cancer Discov. 2011 Nov;1(6):508-23
references.pmid: 22586653
references.citation: N Engl J Med. 2008 Oct 23;359(17):1757-65
references.pmid: 18946061
references.citation: J Clin Oncol. 2008 Apr 1;26(10):1626-34
references.pmid: 18316791
references.citation: Clin Cancer Res. 2007 Mar 1;13(5):1552-61
references.pmid: 17332301
references.citation: Cancer Sci. 2008 Jul;99(7):1471-8
references.pmid: 18422755
references.citation: Nat Med. 2012 Jan 22;18(2):221-3
references.pmid: 22270724
references.citation: N Engl J Med. 2009 Apr 2;360(14):1408-17
references.pmid: 19339720
references.citation: J Clin Oncol. 2009 Feb 10;27(5):663-71
references.pmid: 19114683
references.citation: J Clin Oncol. 2010 Nov 1;28(31):4697-705
references.pmid: 20921465